AU2002350207A1 - Topical delivery of codrugs - Google Patents

Topical delivery of codrugs Download PDF

Info

Publication number
AU2002350207A1
AU2002350207A1 AU2002350207A AU2002350207A AU2002350207A1 AU 2002350207 A1 AU2002350207 A1 AU 2002350207A1 AU 2002350207 A AU2002350207 A AU 2002350207A AU 2002350207 A AU2002350207 A AU 2002350207A AU 2002350207 A1 AU2002350207 A1 AU 2002350207A1
Authority
AU
Australia
Prior art keywords
compounds
constituent
codrug
moiety
skin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2002350207A
Other languages
English (en)
Inventor
Paul Ashton
Grazyna Cynkowska
Tadeusz Cynkowski
Eric Gauthier
Robert Shimzu
Kenneth A Walters
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Control Delivery Systems Inc
Original Assignee
Control Delivery Systems Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Control Delivery Systems Inc filed Critical Control Delivery Systems Inc
Publication of AU2002350207A1 publication Critical patent/AU2002350207A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/12—Keratolytics, e.g. wart or anti-corn preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Ophthalmology & Optometry (AREA)
  • Oncology (AREA)
  • Psychiatry (AREA)
  • Communicable Diseases (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Virology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2002350207A 2001-11-19 2002-11-19 Topical delivery of codrugs Abandoned AU2002350207A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US33151201P 2001-11-19 2001-11-19
US60/331,512 2001-11-19
PCT/US2002/037035 WO2003043657A1 (en) 2001-11-19 2002-11-19 Topical delivery of codrugs

Publications (1)

Publication Number Publication Date
AU2002350207A1 true AU2002350207A1 (en) 2003-06-10

Family

ID=23294274

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2002350207A Abandoned AU2002350207A1 (en) 2001-11-19 2002-11-19 Topical delivery of codrugs

Country Status (6)

Country Link
US (3) US20030118528A1 (enExample)
EP (1) EP1448231A1 (enExample)
JP (1) JP2005518354A (enExample)
AU (1) AU2002350207A1 (enExample)
CA (1) CA2467559A1 (enExample)
WO (1) WO2003043657A1 (enExample)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6417227B1 (en) * 1999-04-28 2002-07-09 Cg And Associates Methods of delivery of cetyl myristoleate
US20040022853A1 (en) * 2001-04-26 2004-02-05 Control Delivery Systems, Inc. Polymer-based, sustained release drug delivery system
CN1520297A (zh) * 2001-04-26 2004-08-11 ���ߵ���Ƶϵͳ��˾ 包含复合药物(codrugs)的缓释药物传递系统
IL158882A0 (en) * 2001-06-05 2004-05-12 Control Delivery Sys Inc Sustained-release analgesic compounds
IN2014DN10834A (enExample) * 2001-09-17 2015-09-04 Psivida Inc
WO2003043657A1 (en) * 2001-11-19 2003-05-30 Control Delivery Systems, Inc. Topical delivery of codrugs
US20030170286A1 (en) * 2001-12-10 2003-09-11 Paul Ashton Treatment of genitourinary tract disorders
US20040022815A1 (en) * 2002-08-05 2004-02-05 Orchid Health Care Novel pharmaceutical composition of ceftiofur
WO2005009480A2 (en) * 2003-06-11 2005-02-03 Control Delivery Systems, Inc. Implants containing codrugs
US8267914B1 (en) * 2003-10-16 2012-09-18 University Of Notre Dame Du Lac Method and apparatus for AC electrospray
AU2004284080B2 (en) * 2003-10-24 2008-10-02 Adhesives Research, Inc. Disintegratable films for diagnostic devices
US9248146B2 (en) * 2003-10-24 2016-02-02 Adhesives Research, Inc. Dissolvable adhesive films for delivery of pharmaceutical or cosmetic agents
CA2467321A1 (en) * 2004-05-14 2005-11-14 Paul J. Santerre Polymeric coupling agents and pharmaceutically-active polymers made therefrom
EP1744787A4 (en) * 2004-05-14 2011-04-06 Interface Biologics Inc POLYMER COUPLING AGENTS AND PHARMACEUTICALLY ACTIVE POLYMERS MANUFACTURED THEREOF
US20060135609A1 (en) * 2004-10-21 2006-06-22 Duke University Ophthamological drugs
US20060105941A1 (en) * 2004-11-12 2006-05-18 Allergan, Inc. Mixed antibiotic codrugs
US20060222692A1 (en) * 2005-03-31 2006-10-05 Fairfield Clinical Trials Llc Method and compositions for transdermal administration of antimicrobial medications
US20070254920A1 (en) * 2006-04-26 2007-11-01 Aerie Pharmaceuticals, Inc. Prodrug derivatives of acids using alcohols with homotopic hydroxy groups and methods for their preparation and use
WO2008115590A1 (en) * 2007-03-21 2008-09-25 Alza Corporation Apparatus and method for transdermal delivery of a benzodiazepine
EP2152359A2 (en) 2007-05-25 2010-02-17 Compex Medical S.A. Wound healing electrode set
BRPI0912820A2 (pt) 2008-05-20 2015-10-13 Neurogesx Inc pró-fármacos de relação hepatoprotetora de acetaminofeno
WO2010022326A2 (en) * 2008-08-22 2010-02-25 Us Worldmeds Llc Transdermal delivery of apomorphine using microneedles
US20100086581A1 (en) * 2008-10-07 2010-04-08 Ernest Bove Method for purpura reduction and prevention
WO2014144073A2 (en) * 2013-03-15 2014-09-18 Rutgers, The State University Of New Jersey Augmenting moieties for anti-inflammatory compounds
US11731991B2 (en) 2008-11-03 2023-08-22 Lehigh University Augmenting moieties for anti-inflammatory compounds
DE102009008256A1 (de) * 2009-02-10 2010-08-12 Lts Lohmann Therapie-Systeme Ag Prodrugs vom Typ N-hydroxylierter Amidine, Guanidine und/oder Aminohydrazone zur Applikation über die Haut
BRPI0900238A2 (pt) * 2009-02-12 2010-10-26 Arch Chem Inc composição antimicrobiana e processo para controle da contaminação microbiana em processos de fermentação alcóolica
PL2403482T3 (pl) 2009-03-04 2018-06-29 Emplicure Ab Preparat odporny na nadużywanie
PL2427177T3 (pl) 2009-05-08 2018-09-28 Emplicure Ab Kompozycja do przedłużonego podawania leku zawierająca geopolimerowy środek wiążący
JP5833007B2 (ja) 2009-08-31 2015-12-16 ドクター・レディーズ・ラボラトリーズ・リミテッド ステロイドを含む局所製剤
WO2012083178A1 (en) 2010-12-17 2012-06-21 Neo Oncology Inc. Methods and devices for using isoperillyl alcohol
US20160038600A1 (en) 2012-08-03 2016-02-11 Neonc Technologies Inc. Pharmaceutical compositions comprising poh derivatives
WO2012032337A2 (en) * 2010-09-07 2012-03-15 Orexo Ab A transdermal drug administration device
EP2630952A1 (en) * 2012-02-23 2013-08-28 Novagali Pharma S.A. Self-preserved oil dispersions comprising boric acid
CN105025929A (zh) 2013-03-08 2015-11-04 阿勒根公司 环孢菌素a-类固醇缀合物
US9402912B2 (en) 2013-03-08 2016-08-02 Allergan, Inc. Antibiotic conjugates directly linked with steroid drugs
BR112015029920A2 (pt) * 2013-06-04 2017-07-25 Lts Lohmann Therapie Systeme Ag sistema de administração transdérmica
US20160184431A1 (en) 2014-03-11 2016-06-30 Promius Pharma Llc Topical compositions comprising a corticosteroid
IL255290B2 (en) 2015-04-27 2024-01-01 Medical Res Infrastructure & Health Services Fund Tel Aviv Medical Ct Substances that bind to EGF1 and their use in the treatment of inflammatory diseases and tumors
MX2018000611A (es) * 2015-07-15 2018-09-06 Celator Pharmaceuticals Inc Sistemas mejorados de entrega de nanoparticula.
US10286095B2 (en) 2015-09-11 2019-05-14 Olson Ip Technologies, Inc. Travel kit
EA037327B1 (ru) 2015-09-22 2021-03-12 Грейбуг Вижн, Инк. Соединения и композиции для лечения глазных расстройств
US11045520B2 (en) * 2016-03-22 2021-06-29 The General Hospital Corporation Compositions and methods for topical delivery of pharmaceutical agents
US20210369666A1 (en) * 2016-10-26 2021-12-02 Thessicar E. ANTOINE Devices and methods for the treatment of a zoonotic herpesvirus infection
AU2018240462C1 (en) 2017-03-23 2022-12-08 Graybug Vision, Inc. Drugs and compositions for the treatment of ocular disorders
CN111201040A (zh) 2017-05-10 2020-05-26 灰色视觉公司 用于医学疗法的缓释微粒及其悬浮液
WO2019148294A1 (en) * 2018-02-02 2019-08-08 Interface Biologics, Inc. Dimeric dexamethasone prodrug compositions and uses thereof
US12473326B2 (en) 2019-02-01 2025-11-18 Ripple Therapeutics Corporation Crystalline forms of dexamethasone dimers and uses thereof
CN114599406A (zh) * 2019-07-10 2022-06-07 波纹疗法公司 包含二聚类固醇前药的表面涂层和可植入装置及其用途
US20220347305A1 (en) 2019-08-07 2022-11-03 Ripple Therapeutics Corporation Controlled release drug dimers
WO2021041800A1 (en) * 2019-08-30 2021-03-04 Remedy Diagnostics LLC Transdermal device comprising pain molecules
WO2021220061A2 (en) 2020-05-01 2021-11-04 Ripple Therapeutics Corporation Heterodimer compositions and methods for the treatment of ocular disorders
CN113332588B (zh) * 2021-05-26 2023-05-09 四川大学 用于口腔黏膜给药的尖端载药可溶性微针贴片及其制备方法

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2999102A (en) * 1959-10-14 1961-09-05 Thomae Gmbh Dr K Bis-(steroid-21)-dicarboxylic acid esters
US3147183A (en) * 1962-04-16 1964-09-01 Boehringer Sohn Ingelheim Bis-(steroid-21)-dicarboxylic acid esters
FR2576213B1 (fr) * 1985-01-21 1989-02-24 Cortial Nouveau procede d'obtention de formes pharmaceutiques a liberation prolongee
US5028431A (en) * 1987-10-29 1991-07-02 Hercon Laboratories Corporation Article for the delivery to animal tissue of a pharmacologically active agent
TW225536B (enExample) * 1990-08-23 1994-06-21 Ciba Geigy Ag
US5681964A (en) * 1990-10-23 1997-10-28 University Of Kentucky Research Foundation Permeable, non-irritating prodrugs of nonsteroidal and steroidal agents
WO1993020079A1 (en) * 1992-04-06 1993-10-14 Biosite Diagnostics Incorporated Novel opiate derivatives and protein and polypeptide opiate derivative conjugates and labels
US5552162A (en) * 1993-02-09 1996-09-03 Arch Development Corporation Method for improvement of scar size and appearance
US6051576A (en) * 1994-01-28 2000-04-18 University Of Kentucky Research Foundation Means to achieve sustained release of synergistic drugs by conjugation
US5703073A (en) * 1995-04-19 1997-12-30 Nitromed, Inc. Compositions and methods to prevent toxicity induced by nonsteroidal antiinflammatory drugs
US5840731A (en) * 1995-08-02 1998-11-24 Virginia Commonwealth University Pain-alleviating drug composition and method for alleviating pain
DE19607395C2 (de) * 1996-02-28 2002-11-21 Lohmann Therapie Syst Lts Salze aus einem kationischen narkotischen Analgetikum mit einem anionischen nichtnarkotischen Analgetikum, Verfahren zu deren Herstellung und die diese Salze enthaltenden pharmazeutischen Präparate
MXPA02001857A (es) * 1999-08-24 2003-07-14 Cellgate Inc Composiciones y metodos para incrementar la entrega de drogas a traves y dentro de tejidos epiteliales.
FR2803849B1 (fr) * 2000-01-19 2002-04-19 Centre Nat Rech Scient Molecules chimeres formees de psoralene et de retinoide, leur procede de preparation, et leurs applications au traitement de pathologies de l'hyperproliferation cellulaire et notamment du psoriasis
US6306842B1 (en) * 2000-06-02 2001-10-23 Medinox, Inc. Protected forms of a combination of pharmacologically active agents and uses therefor
WO2003043657A1 (en) * 2001-11-19 2003-05-30 Control Delivery Systems, Inc. Topical delivery of codrugs
MXPA04006875A (es) * 2002-01-18 2004-12-06 Control Delivery Sys Inc Sistema de gel polimerico para suministro controlado de cofarmacos.

Also Published As

Publication number Publication date
US20030118528A1 (en) 2003-06-26
CA2467559A1 (en) 2003-05-30
JP2005518354A (ja) 2005-06-23
US20070082041A1 (en) 2007-04-12
US20080107720A1 (en) 2008-05-08
EP1448231A1 (en) 2004-08-25
WO2003043657A1 (en) 2003-05-30

Similar Documents

Publication Publication Date Title
US20030118528A1 (en) Topical delivery of codrugs
JP2005518354A5 (enExample)
JP7189983B2 (ja) 異常炎症反応に関連する状態を処置するための方法および組成物
US20040180036A1 (en) Salts of codrugs and uses related thereto
US11324705B2 (en) Transdermal drug delivery system
AU2003205278B2 (en) Polymeric gel system for the controlled delivery of codrugs
US10179159B2 (en) Topical anesthetic formulation
EP2123274B1 (en) Medicinal composition for transdermal absorption, medicinal composition storing unit and transdermal absorption preparation using the same
CA2466536C (en) Transdermal transport of compounds
JP5628467B2 (ja) 生体分解性徐放性ドラッグデリバリーシステム
PT1962817E (pt) Administração transdérmica de uma forma de sal de meptazinol
US20230128252A1 (en) Pharmaceutical compositions
ES2470367T3 (es) Preparaciones farmacéuticas para uso transd�rmico
TW200526272A (en) Suspension delivery system for the sustained and controlled local release of pharmaceuticals
Mathews et al. Management of pain using transdermal patches-a review
WO2014176417A1 (en) Topical preparation for bypassing gi tract, delivery of therapeutics, and trans-epithelial drug delivery system
JP2004524270A (ja) 長時間作用する麻酔薬および鎮痛薬としての、三環式抗うつ薬およびのそれらのアナログ
WO2005009480A2 (en) Implants containing codrugs
JP3313893B2 (ja) 経皮吸収促進剤及び皮膚外用剤
ES2356563T3 (es) Administración transdérmica de meptazinol.
JP3313892B2 (ja) 経皮吸収促進剤及び皮膚外用剤
JP3313890B2 (ja) 経皮吸収促進剤及び皮膚外用剤
Hu Transdermal and transbuccal drug delivery: enhancement using iontophoresis and chemical enhancers
JPH083070A (ja) 経皮吸収促進剤及び皮膚外用剤
JP2001163781A (ja) 皮膚組織障害治療・予防・改善用外用剤

Legal Events

Date Code Title Description
MK4 Application lapsed section 142(2)(d) - no continuation fee paid for the application